Astrana Health reported Q3 CY2025 results with sales up 99.7% year on year to $956 million, beating revenue expectations but missing EPS estimates. The company lowered full-year revenue guidance to $3.14 billion, 2.2% below analysts’ estimates. Operating margin was 2%, down from 5.9% last year. EPS was $0.01, significantly below consensus estimates. Astrana Health’s stock price dropped 1.5% following the results. Despite the strong revenue growth, profitability metrics like operating margin and EPS show room for improvement. The company’s long-term growth and historical financial performance provide valuable insights for potential investors.

Read more at Stock Story Media: Astrana Health (NASDAQ:ASTH) Beats Q3 Sales Expectations